Also known as SLU PP 332
A synthetic small-molecule pan-ERR agonist studied as an “exercise mimetic” — not a peptide.
Research refreshed
SLU-PP-332 is a synthetic small molecule — not a peptide — that activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ), the orphan nuclear receptors that control oxidative metabolism and mitochondrial biogenesis. It is studied as an “exercise mimetic”: in preclinical work it increased a type of muscle fiber and oxidative metabolism and reduced fat mass in mice without changes in food intake or activity. It is an early research compound with no human data and no approval.
SLU-PP-332 came out of medicinal-chemistry work (Burris and colleagues) to find a direct agonist of the estrogen-related receptors, which sit downstream of PGC-1α and govern how cells build mitochondria and burn fat. Activating that program pharmacologically is the idea behind an “exercise mimetic” — reproducing some transcriptional effects of endurance exercise without the exercise.
In mouse studies the compound raised oxidative (fatigue-resistant) muscle fiber content and energy expenditure and reduced fat mass and diet-induced obesity. All of this is preclinical: there is no clinical trial, no safety data in humans, and it is a research chemical rather than a peptide or an approved drug.
Pan-ERR (ERRα/β/γ) agonism, upregulating the PGC-1α/ERR transcriptional program for mitochondrial biogenesis, fatty-acid oxidation, and oxidative muscle metabolism.
Behind every vial of SLU-PP-332 is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how SLU-PP-332, specifically, is brought into being.
SLU-PP-332 begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
SLU-PP-332 is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — SLU-PP-332 plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of SLU-PP-332 proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of SLU-PP-332 — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Not a peptide — a synthetic small molecule made by conventional organic synthesis. Its purity and identity are an organic-chemistry question answered by HPLC and NMR/mass spectrometry, not by peptide solid-phase synthesis or a peptide-style certificate. Vendor material described with a peptide CoA is a red flag that the wrong analysis was run.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
A synthetic small-molecule agonist of the estrogen-related receptors (ERRα/β/γ), studied as an exercise mimetic that boosts oxidative metabolism in preclinical models. It is not a peptide.
It activates the PGC-1α/ERR transcriptional program that endurance exercise normally engages — mitochondrial biogenesis and fat oxidation — pharmacologically rather than through exercise.
No. The published work is in mice; there is no clinical trial or human safety data.
No — it is an early research compound, not FDA-approved. This page is a research and educational reference.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.